Skip to main content

Published locations for Ibrutinib+BR a promising treatment option for newly diagnosed MCL ineligible for intensive therapy

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ibrutinib+BR a promising treatment option for newly diagnosed MCL ineligible for intensive therapy

User login

  • Reset your password
  • /content/ibrutinibbr-promising-treatment-option-newly-diagnosed-mcl-ineligible-intensive-therapy
  • /hematology-oncology/article/262407/b-cell-lymphoma/ibrutinibbr-promising-treatment-option-newly
  • /b-cell-lymphoma-icymi/article/262407/b-cell-lymphoma/ibrutinibbr-promising-treatment-option-newly